Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. has 103.14M shares outstanding.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. maintains a current ratio of 3.34, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.54, indicating elevated leverage, while an interest coverage ratio of 78.91 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. posted a return on equity (ROE) of 14.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.60 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.83, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.05, useful for judging operating efficiency across full business cycles. The company generates approximately 1.01M in revenue per employee across its workforce of 15,334.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.75 indicates how many times Regeneron Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. recorded 837.30M in income tax expense. That works out to an effective tax rate of 16.21, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.17B, leaving 4.33B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on August 18, 2026, Regeneron Pharmaceuticals, Inc.'s stock has gained approximately 18.36% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. generated 15.53B in revenue and converted that into 4.33B in net income, yielding earnings per share of 40.42. EBITDA reached 4.37B, while operating income came in at 4.17B.

As of June 30, 2026, Regeneron Pharmaceuticals, Inc. holds 7.99B in cash and equivalents against 2.71B in total debt, resulting in a net debt position of -469.20M. Total book value stands at 31.71B, with working capital of 12.92B providing operational flexibility.

Regeneron Pharmaceuticals, Inc. produced 4.68B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -185.20M in capital expenditures, free cash flow totaled 4.50B - equivalent to 43.51 per share.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. posted a gross margin of 84.86, reflecting its pricing power and cost economics. The operating margin of 26.87 and net profit margin of 27.86 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Regeneron Pharmaceuticals, Inc. paid dividends of 3.66 per share. The dividend payout ratio of 8.74 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.